In Vitro: Myriocin (Thermozymocidin; 0-10000 nM; 96 h; Huh7/Rep-Feo cells) inhibits the replication of a subgenomic hepatitis C virus (HCV) genotype 1b replicon. Myriocin (100 nM; 72 h) decreases in the sphingomyelin content of Huh7 cells.
In Vivo: Myriocin (Thermozymocidin; 0-1 mg/kg; i.p.; daily, for 5 d; male Balb/c mice) blocks de novo synthesis of sphingolipids in vivo by SPT inhibition and induced c-myc expression in liver.